USA domestic sarms GW-501516 Cardarine powder

GW-501516 is a unique medication officially classified as a PPAR receptor agonist (PPAR-RA). Research for this medication began in 1992 in a conjoined effort between GlaxoSmithKline (GSK) and Ligand Pharmaceuticals. Research into this product was set forth in an effort to provide treatment for various cardiovascular diseases, as well as diabetes, obesity and other conditions. It was soon discovered that the PPAR-RA was highly effective at enhancing endurance, but it was also shown to carry a high potential cost. It was discovered that GW-501516 increased the chances of cancer significantly, and as a result, GSK dropped all further research. However, the studies that produced cancerous results used doses of GW-501516 that were 500 to even 1000 times the amount that a human being would take. If cancer is a risk with standard dosing is unknown.